Anaemia in a phase 2 study of a blood stage falciparum malaria vaccine
2011

Impact of a Malaria Vaccine on Anaemia in Children

Sample size: 300 publication 10 minutes Evidence: moderate

Author Information

Author(s): Ellis Ruth D, Fay Michael P, Sagara Issaka, Dicko Alassane, Miura Kazutoyo, Guindo Merepen A, Guindo Aldiouma, Sissoko Mahamadou S, Doumbo Ogobara K, Diallo Dapa

Primary Institution: National Institute of Allergy and Infectious Diseases, National Institutes of Health (NIAID/NIH), Rockville, Maryland, USA

Hypothesis

Does the AMA1-C1/Alhydrogel malaria vaccine increase the incidence of anaemia in children?

Conclusion

The study found that the malaria vaccine AMA1-C1/Alhydrogel was associated with a higher incidence of anaemia in children compared to the comparator vaccine.

Supporting Evidence

  • The vaccine group had a risk of anaemia twice that of the comparator group.
  • Children with lower baseline haemoglobin were more likely to experience anaemia.
  • Statistical models showed significant results even after adjusting for confounding factors.

Takeaway

Kids who got the malaria vaccine had more problems with low blood levels than those who got a different vaccine.

Methodology

The study used a multiplicative intensity model to analyze the incidence of anaemia in children receiving the vaccine compared to a control group.

Potential Biases

There may be an imbalance in baseline haemoglobin levels between the vaccine and comparator groups.

Limitations

The results should be interpreted with caution as they are based on secondary analyses and may not be confirmatory.

Participant Demographics

Children aged 2-3 years from Mali.

Statistical Information

P-Value

0.0035

Confidence Interval

[1.26, 3.20]

Statistical Significance

p<0.05

Digital Object Identifier (DOI)

10.1186/1475-2875-10-13

Want to read the original?

Access the complete publication on the publisher's website

View Original Publication